Research ArticleCancer
C-reactive protein promotes bone destruction in human myeloma through the CD32–p38 MAPK–Twist axis
- View ORCID ProfileJing Yang1,2,*,†,
- View ORCID ProfileZhiqiang Liu2,3,*,
- View ORCID ProfileHuan Liu2,*,
- Jin He2,
- Jianling Yang2,
- Pei Lin4,
- View ORCID ProfileQiang Wang5,
- View ORCID ProfileJuan Du6,
- Wencai Ma2,
- View ORCID ProfileZheng Yin7,
- View ORCID ProfileEric Davis2,
- Robert Z. Orlowski2,
- View ORCID ProfileJian Hou6, and
- View ORCID ProfileQing Yi5,†
- 1Guangzhou Key Laboratory of Translational Medicine on Malignant Tumor Treatment, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China.
- 2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- 3Department of Physiology and Pathology, Tianjin Medical University, Tianjin 300070, China.
- 4Department of Hematopathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- 5Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- 6Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200085, China.
- 7Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Houston, TX 77030, USA.
- ↵†Corresponding author. Email: yiq{at}ccf.org (Q.Y.); jiyang{at}mdanderson.org (J.Y.)
↵* These authors contributed equally to this work.
See allHide authors and affiliations
Science Signaling 12 Dec 2017:
Vol. 10, Issue 509, eaan6282
DOI: 10.1126/scisignal.aan6282
Vol. 10, Issue 509, eaan6282
DOI: 10.1126/scisignal.aan6282
Jing Yang
1Guangzhou Key Laboratory of Translational Medicine on Malignant Tumor Treatment, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou 510095, China.
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zhiqiang Liu
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
3Department of Physiology and Pathology, Tianjin Medical University, Tianjin 300070, China.
Huan Liu
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jin He
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jianling Yang
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Pei Lin
4Department of Hematopathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Qiang Wang
5Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Juan Du
6Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200085, China.
Wencai Ma
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zheng Yin
7Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Houston, TX 77030, USA.
Eric Davis
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Robert Z. Orlowski
2Department of Lymphoma/Myeloma, Division of Cancer Medicine, and the Center for Cancer Immunology Research, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jian Hou
6Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, The Second Military Medical University, Shanghai 200085, China.
Qing Yi
5Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
